SOURCE: BioMedReports


June 27, 2011 08:00 ET

Importance of Rapid HIV Testing Highlighted in Special Report for Investors

LOS ANGELES, CA--(Marketwire - Jun 27, 2011) - As the U.S. marks National HIV Testing Day today, a special report about the emerging need for rapid HIV tests focuses on the efforts of one company in particular: Chembio Diagnostics, Inc.

The success of, as well as certain limitations of, existing rapid screening assays has motivated Chembio to develop a next-generation testing approach that it has named Dual Path Platform (DPP®) technology, for which the company received a United States patent in 2007. (The initial focus for DPP® is rapid HIV testing, but it can be adapted to test for many infectious diseases.) The company's tests are designed to significantly reduce the time to diagnosis and to reduce the costs of testing assumed by healthcare providers.

A brief on what this technology could mean for biotech investors is available now at BioMedReports -- home of the Complete Database of Trade Catalysts, Clinical Trials and Upcoming FDA and World-Wide Regulatory Decisions.

Find today's special report on Chembio Diagnostics today at:

In addition, investors interested in make more profitable trades and upcoming news catalysts can our trade alerts at:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556